Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Acasti Pharma ( (ACST) ) has shared an announcement.
At a recent shareholder meeting with strong attendance, several key decisions were made affecting the company’s future. Shareholders elected director nominees and appointed KPMG as the independent auditor. Additionally, executive compensation was approved on an advisory basis. The company will undergo a significant transition, moving from Québec to British Columbia, and then further domesticating to Delaware. Finally, the shareholders sanctioned the 2024 Equity Incentive Plan, setting the stage for strategic corporate and financial advancements.
For detailed information about ACST stock, go to TipRanks’ Stock Analysis page.